Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.

@article{ByakikaKibwika2008SteadystatePC,
  title={Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.},
  author={Pauline Byakika-Kibwika and Mohammed Lamorde and Francis Kalemeera and Antonio D'Avolio and S. Mauro and Giovanni di Perri and M{\'a}ir{\'i}n Ryan and Harriet Mayanja-Kizza and Saye Khoo and David J. Back and Marta Boffito and Concepta Merry},
  journal={The Journal of antimicrobial chemotherapy},
  year={2008},
  volume={62 5},
  pages={1113-7}
}
BACKGROUND We aimed to compare the steady-state pharmacokinetic parameters and tolerability of Triomune 40 (stavudine 40 mg, lamivudine 150 mg and nevirapine 200 mg) and branded formulations of these drugs in HIV-infected Ugandans. METHODS This includes a randomized, open-label, cross-over study of HIV-infected patients stable on therapy for 1 month. Patients were randomized to generic or branded formulation. Plasma pharmacokinetics were assessed after 1 month. The following day, alternate… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Universal Access: National HIV & AIDS Strategic Plan 2007/2008-2011/2012

  • UAC. Moving Toward
  • Republic of Uganda: Uganda AIDS Commission,
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…